The Europe Alzheimer’s Disease Therapeutics and Diagnostics Market was worth USD 2822 Million in 2018 and estimated to be growing at a CAGR of 4.76%, to reach USD 3560 Million by 2023. Alzheimer’s disease is a neurodegenerative, progressive, non-reversible ailment that is caused due to irregular functioning of brain cells i.e. breakdown of synaptic communication, ensuing in the loss of cerebral functions.
Certain signs and indications of Alzheimer’s disease are memory loss, sleeplessness, recurring movements, anxiety, despair and loss of reasoning capabilities. All memory and cerebral functioning may be lost in the advanced stages of the disease. According to the International Institute of Aging, Alzheimer’s disease is the most frequent form of dementia.
The growth of the Europe Alzheimer’s disease Therapeutics and Diagnostics Market is mainly driven by factors such as rising geriatric populace, upsurge in healthcare spending and increasing government subsidy. In addition, growing healthcare cognizance and innovative diagnostic technologies are also stimulating the growth of the market. However, several factors such as stringent regulations, long authorization time for new medicines, and expiration of numerous patent drugs are restraining the growth of the Alzheimer’s disease Therapeutics and Diagnostics market in this region.
The Europe Alzheimer’s Disease Therapeutics and Diagnostics market is segmented based on Therapeutics and Diagnostics. The market for Alzheimer’s disease Therapeutics and Diagnostics, on the basis of Therapeutics is segmented into Marketed Drugs and Pipeline Drugs. Marketed Drugs are further segmented into NMDA Receptor Antagonists and Cholinesterase Inhibitors. Marketed Drugs lead the market on the basis of Therapeutics due to a large user base. On the basis of Diagnostics, the Alzheimer’s disease Therapeutics and Diagnostics market is segmented into Computed tomography scan, Electroencephalography, Lumbar puncture test, Magnetic resonance imaging, Positron emission tomography, and Others. Under this segment, Computed tomography scan segment leads the Alzheimer’s disease Therapeutics and Diagnostics market. Absence of alternative imaging tool for brain and neurological diagnostics is one of the crucial reasons for its large share.
The Europe market has been geographically segmented into Germany, U.K, France, Spain, and Italy. Populations in Europe are ageing, and with this will grow the frequency of Alzheimer’s disease. Roughly around 9 million people in the EU are projected to have dementia by 2030 – approaching twice the population of Denmark. Increasing R&D activity and a strong pipeline of disease modifying drugs are the crucial factors driving the growth of the market in this region.
Leading companies have applied tactics such as mergers & acquisitions, collaborations, and joint ventures to gain a strong foothold in the market. The major companies dominating the Alzheimer’s Disease Therapeutics and Diagnostics market in this region are Abbvie Inc., Pfizer Inc., AC Immune SA, Eisai Co Ltd., Allergan PLC, Novartis AG, Amarantus Bioscience Holdings, H. Lundbeck A/S, Anavex LifeSciences, Avid Radiopharmaceuticals, Forest Laboratories Inc., Axon Neuroscience, Daiichi Sankyo Co, TauRx Therapeutics Ltd, Eli Lilly, F. Hoffmann La Roche AG, Johnson & Johnson, GE Healthcare, Janssen Pharmaceuticals etc.
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Therapeutics
5.1.1 Introduction
5.1.2 Marketed Drugs
5.1.2.1 NMDA Receptor Antagonists
5.1.2.2 Cholinesterase Inhibitors
5.1.3 Pipeline Drugs
5.1.4 Y-o-Y Growth Analysis, By Therapeutics
5.1.5 Market Attractiveness Analysis, By Therapeutics
5.1.6 Market Share Analysis, By Therapeutics
5.2 Diagnostics
5.2.1 Introduction
5.2.2 Computed tomography scan
5.2.3 Electroencephalography
5.2.4 Lumbar puncture test
5.2.5 Magnetic resonance imaging
5.2.6 Positron emission tomography
5.2.7 Others
5.2.8 Y-o-Y Growth Analysis, By Diagnostics
5.2.9 Market Attractiveness Analysis, By Diagnostics
5.2.10 Market Share Analysis, By Diagnostics
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Therapeutics
6.1.3.3 By Diagnostics
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Therapeutics
6.1.4.3 By Diagnostics
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Therapeutics
6.1.5.3 By Diagnostics
6.2 U.K
6.3 Spain
6.4 Germany
6.5 Italy
6.6 France
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 Abbvie Inc.
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Pfizer Inc.
8.3 AC Immune SA
8.4 Eisai Co Ltd.
8.5 Allergan PLC
8.6 Novartis AG
8.7 Amarantus Bioscience Holdings
8.8 H. Lundbeck A/S
8.9 Anavex LifeSciencescs
8.10 Avid Radiopharmaceuticals
8.11 Forest Laboratories Inc.
8.12 Axon Neuroscience
8.13 Daiichi Sankyo Co
8.14 TauRx Therapeutics Ltd
8.15 Eli Lilly
8.16 F. Hoffmann La Roche AG
8.17 Johnson & Johnson
8.18 GE Healthcare
8.19 Janssen Pharmaceuticals
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
